Request a Quote

2026 Global Tuberculosis Report: Key Data and What It Means

The UN health agency released the 2026 global tuberculosis report on November 12, 2026. It estimates 10.6 million people fell ill with tuberculosis worldwide in 2025, about 75,000 fewer than in 2024, and that tuberculosis caused 1.13 million deaths. TB remains the world's leading infectious killer, and TB disease burden is high. Cases and deaths are falling, but progress is too slow to meet the 2025 End TB Strategy milestones.

Why this report matters

Tuberculosis is still a major infectious disease, and TB disease remains a leading public health problem. Its epidemiology varies by region. The burden is falling in much of the world, but most regions are moving too slowly to meet the 2030 targets of the global End TB Strategy. The report, published on November 12, 2026, draws on national surveillance data to show where the epidemic stood at the end of 2025.

How the data were estimated

The estimates come from national TB surveillance systems and disease surveillance, compiled with the national TB prevention and control center of the national disease-control agency. Unless noted, all figures refer to the end of 2025. Estimates come with uncertainty ranges shown as 95 percent confidence intervals. Reported case counts are the number of newly diagnosed and notified patients.

Table 1. Data sources and reference periods

Item

Basis

Reference period

Estimated cases and deaths

National TB surveillance data compiled with the national TB control center

End of 2025

Uncertainty ranges

95 percent confidence intervals

End of 2025

Drug resistance data

Rapid diagnostic testing results

2025

Treatment outcomes

Treatment registers for patients starting therapy

2023 cohort

What the 2026 global tuberculosis report says about TB today

The report puts the 2025 estimate at 10.6 million new patients, about 75,000 fewer than in 2024. That continues a decline that started in 2024, after three straight years of increase from 2021 to 2023. Even so, the total remains above the 2020 level.

Table 2. Global tuberculosis estimates, 2025 versus 2024

Indicator

2025

2024

Change

Estimated new tuberculosis patients

10.6 million

not stated

down about 75,000

Incidence rate per 100,000 people

129

131

down 1.6 percent

Newly diagnosed and reported patients

8.4 million

not stated

79 percent of estimated incidence

First diagnosis by rapid test

59 percent

54 percent

up 5 percentage points

Tuberculosis deaths

1.13 million

1.18 million

down 4 percent

Regionally, new cases in 2025 were concentrated in South-East Asia (35 percent), the Western Pacific (27 percent), and Africa (25 percent), with smaller shares in the Eastern Mediterranean (8.7 percent), the Americas (3.4 percent), and Europe (1.7 percent). Case notification levels tracked these regional differences. Eight countries account for two thirds of all cases: India (about 25 percent), Indonesia (10 percent), the Philippines (6.8 percent), China (6.5 percent), Pakistan (6.4 percent), Nigeria (4.9 percent), the Democratic Republic of Congo (3.9 percent), and Bangladesh (3.7 percent). These are high-burden TB countries. The top five countries together exceed half the global total.

From 2015 to 2025, TB incidence fell 42 percent in Europe and 30 percent in Africa. They were the only two regions to reach the first 2020 milestone of the End TB Strategy. South-East Asia fell 18 percent, the Eastern Mediterranean 6.6 percent, the Western Pacific showed no net change, and the Americas rose 13 percent.

Tuberculosis deaths in 2025

Tuberculosis caused an estimated 1.13 million deaths in 2025, including about 1.0 million among people without HIV and 137,000 among people living with HIV. That is roughly twice the number of HIV/AIDS deaths (570,000) and about twice malaria deaths. The global case fatality rate is about 11 percent, and the treatment success rate for drug-sensitive tuberculosis is about 90 percent.

TB mortality fell 4 percent from 2024 and 35 percent from 1.74 million in 2015. The reduction reached the first 2020 milestone, though five years later than planned, and remains far from the 2030 target of a 90 percent cut. Europe and Africa cut deaths by about half from 2015 levels (down 51 percent and 50 percent). South-East Asia fell 31 percent, the Eastern Mediterranean 8.6 percent, the Western Pacific 5.2 percent, while deaths in the Americas rose 14 percent.

Drug-resistant tuberculosis

The report estimates 370,000 people with multidrug-resistant or rifampicin-resistant tuberculosis (MDR/RR-TB) in 2025, about 3.5 percent of all cases and slightly lower than in 2024, and drug-resistant TB remains a concern. Among new patients, 3.1 percent had drug-resistant disease, down from 3.2 percent in 2024 and 4.4 percent in 2015. Among previously treated patients, the rate was 14.8 percent, down from 15.3 percent in 2024 and 20 percent in 2015.

China reported 26,000 MDR/RR-TB patients in 2025, ranking third worldwide. China, India, the Philippines, and the Russian Federation together account for more than half of all MDR/RR-TB patients globally.

Focus on China

China reported an estimated 685,000 new tuberculosis patients in 2025, down from 696,000 in 2024, with an incidence rate of 48 per 100,000 people. China ranks fourth among the 30 high-burden countries and accounts for 6.5 percent of global tuberculosis cases. In 2024 China first entered the group of medium-low burden countries.

Tuberculosis deaths in China fell to 26,000 in 2025 (28,000 in 2024), with a mortality rate of 1.8 per 100,000 people. Deaths are down 35 percent from 2015 and incidence is down 20 percent from the 2015 baseline, so China met the first milestone of the End TB Strategy on both measures.

Counterintuitive conclusions

Three findings deserve attention. First, tuberculosis is the world's leading infectious killer, but global investment in TB research was only 1.2 billion dollars in 2023, about 24 percent of the 5 billion dollars annual target for 2027. Second, the Western Pacific region, which includes China, showed no net change in incidence from 2015 to 2025, while Europe and Africa cut deaths by about half. Third, about 2.2 million people estimated to have tuberculosis in 2025 were never diagnosed or reported. Roughly 60 percent of that gap sits in just ten countries.

Practical recommendations

The 2026 global tuberculosis report points to five priorities for national tuberculosis programs:

  • Expand rapid testing: tuberculosis diagnosis still relies on rapid methods, used in only 59 percent of first diagnoses in 2025, well short of the 100 percent target for 2027.
  • Scale up drug-resistant treatment: only 155,333 MDR/RR-TB patients received TB treatment, equal to 42 percent of estimated cases, and 42 percent of those treated used the shorter six-month regimen, up from 18 percent in 2024, a meaningful curb on antimicrobial resistance.
  • Expand preventive treatment: 5.2 million people at high risk received TB preventive treatment in 2025, but coverage is only 26 percent for close contacts and 60 percent for people living with HIV.
  • Address catastrophic costs: about half of tuberculosis patient households face catastrophic health expenditure.
  • Increase domestic funding: 86 percent of TB funding for diagnosis and treatment already comes from domestic sources, yet total funding is only 30 percent of the 22 billion dollars annual target for 2027.

Limitations

The estimates are model-based and carry uncertainty intervals, and surveillance quality varies by country. The gap between estimated and reported cases reflects underdiagnosis and underreporting, not a lack of disease. Updated figures for 2026 will come out in December 2026, and country comparisons are affected by different surveillance methods, health system capacity, and universal health coverage.

Bottom line

The 2026 global tuberculosis report shows that tuberculosis remains the world's leading infectious killer, causing about 1.13 million deaths in 2025. Cases and deaths are falling, but too slowly: incidence is down only 14 percent since 2015 against a 50 percent milestone for 2025, and deaths are down 35 percent against a 75 percent milestone. Closing the 2.2 million-case reporting gap, expanding rapid testing and preventive treatment, and closing the funding shortfall are the fastest ways to accelerate progress.

FAQ

What is the 2026 global tuberculosis report

The 2026 global tuberculosis report is the annual assessment of the tuberculosis epidemic by the UN health agency. Released on November 12, 2026, it brings together national surveillance data to estimate how many people fell ill with tuberculosis, how many died, how many were diagnosed and treated, and how countries are progressing toward the goals of the global End TB Strategy.

How many people had tuberculosis in 2025

The report estimates that 10.6 million people fell ill with tuberculosis worldwide in 2025, with a 95 percent confidence interval of 9.8 to 11.4 million. That is about 75,000 fewer than in 2024 and marks the second straight year of decline. The global incidence rate was 129 cases per 100,000 people.

How many people died of tuberculosis in 2025

Tuberculosis caused an estimated 1.13 million deaths in 2025, including about 1.0 million among people without HIV and 137,000 among people living with HIV. Deaths fell 4 percent from 2024 and 35 percent from 2015. TB deaths are roughly twice the number of HIV/AIDS deaths (570,000) and about twice malaria deaths.

Which countries have the most tuberculosis cases

Eight countries account for two thirds of all tuberculosis cases worldwide: India (about 25 percent), Indonesia (10 percent), the Philippines (6.8 percent), China (6.5 percent), Pakistan (6.4 percent), Nigeria (4.9 percent), the Democratic Republic of Congo (3.9 percent), and Bangladesh (3.7 percent). Together the 30 high-burden countries represent 88 percent of estimated new cases.

How is China doing on tuberculosis

China reported an estimated 685,000 new tuberculosis patients in 2025, down from 696,000 in 2024, with an incidence rate of 48 per 100,000. China ranks fourth among the 30 high-burden countries and accounts for 6.5 percent of global cases. TB deaths fell to 26,000, 35 percent below the 2015 level, meeting the first milestone of the End TB Strategy.

What is drug resistant tuberculosis

Drug-resistant tuberculosis, specifically multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB), resisted the most powerful first-line medicines. The report estimates 370,000 MDR/RR-TB patients worldwide in 2025, about 3.5 percent of all cases. Rates were 3.1 percent among new patients and 14.8 percent among previously treated patients.

How many people get treatment for tuberculosis

Of the 8.4 million people newly diagnosed and reported in 2025, treatment success for drug-sensitive tuberculosis is about 90 percent. For MDR/RR-TB, 155,333 patients received treatment, equal to 42 percent of estimated cases, and 42 percent of those treated used the shorter six-month regimen, up from 18 percent in 2024.

What is tuberculosis preventive treatment

Tuberculosis preventive treatment protects people at high risk of developing the disease. In 2025, 5.2 million people received it, including 3.7 million close contacts of confirmed patients (26 percent coverage) and 1.5 million people living with HIV (60 percent coverage). Coverage rose slightly from 2024 but remains far below the 2027 target of 90 percent.

Why are tuberculosis deaths falling slowly

TB deaths fell 35 percent from 2015 to 2025, reaching the first milestone five years late, and are still far from the 2030 goal of a 90 percent reduction. Progress is uneven: Europe and Africa cut deaths by about half, while deaths rose 14 percent in the Americas. About half of TB patient households still face catastrophic costs.

How is tuberculosis research funded

Global investment in tuberculosis research was 1.2 billion dollars in 2023, only 24 percent of the 5 billion dollars annual target set for 2027. As of August 2026, 12 tuberculosis vaccine candidates were in clinical development, with three in Phase III trials. Research funding remains far short of what is needed.

What are the biggest challenges for tuberculosis control

The main challenges are the gap between estimated illness and reported diagnosis, about 2.2 million people with tuberculosis were not reported in 2025, slow progress toward the End TB Strategy milestones, catastrophic costs for about half of patient households, declining international donor funding, and research investment well below target.

How does tuberculosis compare with HIV and malaria as a cause of death

Tuberculosis is the world's leading infectious killer. Its 1.13 million deaths in 2025 were about twice the number of HIV/AIDS deaths (570,000) and about twice malaria deaths. TB ranked as the 13th leading cause of death overall and appeared in the top ten causes of death in the African and South-East Asia regions.

My Instagram